Phase 3 Clinical Trials With Primary Completion Dates in November 2025
This is a list of Phase 3 trials with primary completion dates in November 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| BBNX | Beta Bionics, Inc. | 2025-11-01 | Phase 3 | NCT06449677 | Bionic Pancreas in CFRD |
| BHVN | Biohaven Ltd. | 2025-11-01 | Phase 3 | NCT04641143 | Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder |
| CZMWY | Carl Zeiss Meditec AG | 2025-11-01 | Phase 3 | NCT02685605 | Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme |
| DBVT | DBV Technologies S.A. | 2025-11-01 | Phase 3 | NCT05741476 | Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age |
| DBVTF | DBV TECHNOLOGIES | 2025-11-01 | Phase 3 | NCT05741476 | Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age |
| GOSS | Gossamer Bio, Inc. | 2025-11-01 | Phase 3 | NCT05934526 | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) |
| TLX | Telix Pharmaceuticals Limited | 2025-11-01 | Phase 3 | NCT04876651 | The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only |